Atatürk Üniversitesi Atatürk Üniversitesi
Ara
Yayınlara dön
Makale Tam Makale Uluslararası 2025

Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)

Sedat Şen, Murat KÜRTÜNCÜ, Serkan Demir, Tuncay GÜNDÜZ, Ezgi Demirel, MELİH TÜTÜNCÜ, Cihat Uzunkopru, Damla Cetinkaya Tezer, FERAH KIZILAY, Belgin Petek Balci, Gokhan Arslan, Caner Feyzi Demir, Nazire Pinar Acar Ozen, Yesim Beckmann, Ipek Gungor Dogan, Ugur Uygunoglu, Serkan Ozakbas, Mesrure Koseoglu, Haluk Gumus, Nuray Bilge, Durdane Aksoy, Ahmet Kasim Kilic, Mehmet Fatih Yetkin, Aylin Akcali, Sibel Canbaz Kabay, Ozlem Ethemoglu, Nermin Tepe, Vedat Cilingir, Sena Destan Bunul, Dilcan Kotan, Seyda Figul Gokce, Nazli Gamze Bulbul, Fatma Akkoyun Arikan, Sabahattin Saip, Murat Terzi, Husnu Efendi, Rana Karabudak, Aksel Siva, Asli Tuncer

JOURNAL OF NEUROIMMUNOLOGY Cilt 407 · 01.10.2025
DOI ile aç

Özet

Background: Azathioprine (AZA) and rituximab (RTX) are frequently used drugs in the treatment of Myelin Oligodendrocyte Glycoprotein Associated Disease (MOGAD). Objectives: The aim of this study was to evaluate the efficacy and safety data of AZA and RTX treatments in MOGAD. Methods: Patients diagnosed according to the 2023 MOGAD diagnostic criteria and receiving AZA or RTX treatment were included in the study. Results: In 142 patients included in the study, the female/male value was 1.2. The rate of OCB positivity in MOGAD patients was 22.6 %. Patients on RTX had higher EDSS values than patients on AZA. However, the RTX group demonstrated a more pronounced improvement in disability, reflected by a greater negative trend in the Delta EDSS values. The attack-free rate was 78 % in the RTX group and 68 % in the AZA group during their treatment period. Both groups had no difference in the time of the first attack. The main factor affecting the time to first attack was having a higher EDSS at the time of treatment initiation. The survival analysis found that EDSS scores improved significantly in patients treated with RTX. Conclusion: Although survival analyses for both treatments appear to be similar, using RTX provides better EDSS scores.

Sürdürülebilir Kalkınma Amaçları

  • SKA 3: Sağlıklı Bireyler

Atıf için künye

Şen, S., KÜRTÜNCÜ, M., Demir, S., GÜNDÜZ, T., Demirel, E., TÜTÜNCÜ, M., Uzunkopru, C., Tezer, D. C., KIZILAY, F., Balci, B. P., Arslan, G., Demir, C. F., Ozen, N. P. A., Beckmann, Y., Dogan, I. G., Uygunoglu, U., Ozakbas, S., Koseoglu, M., Gumus, H., … Tuncer, A. (2025). Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD). JOURNAL OF NEUROIMMUNOLOGY, 407. https://doi.org/10.1016/j.jneuroim.2025.578686

BibTeX 
@article{sen2025-237839,
  author = {Şen, Sedat and KÜRTÜNCÜ, Murat and Demir, Serkan and GÜNDÜZ, Tuncay and Demirel, Ezgi and TÜTÜNCÜ, MELİH and Uzunkopru, Cihat and Tezer, Damla Cetinkaya and KIZILAY, FERAH and Balci, Belgin Petek and Arslan, Gokhan and Demir, Caner Feyzi and Ozen, Nazire Pinar Acar and Beckmann, Yesim and Dogan, Ipek Gungor and Uygunoglu, Ugur and Ozakbas, Serkan and Koseoglu, Mesrure and Gumus, Haluk and Bilge, Nuray and Aksoy, Durdane and Kilic, Ahmet Kasim and Yetkin, Mehmet Fatih and Akcali, Aylin and Kabay, Sibel Canbaz and Ethemoglu, Ozlem and Tepe, Nermin and Cilingir, Vedat and Bunul, Sena Destan and Kotan, Dilcan and Gokce, Seyda Figul and Bulbul, Nazli Gamze and Arikan, Fatma Akkoyun and Saip, Sabahattin and Terzi, Murat and Efendi, Husnu and Karabudak, Rana and Siva, Aksel and Tuncer, Asli},
  title = {Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)},
  journal = {JOURNAL OF NEUROIMMUNOLOGY},
  year = {2025},
  volume = {407},
  issn = {0165-5728},
  doi = {10.1016/j.jneuroim.2025.578686},
  url = {https://akademik.atauni.edu.tr/yayinlar/237839-comparative-efficacy-of-rituximab-versus-azathioprine-in-the-treatment-of-mog}
}